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Abstract 
Liquid chromatography-electrospray ionisation-mass spectrometry (LC-ESI-MS) platforms are widely 
used to perform high throughput untargeted profiling of biological samples for metabolomics-based 
approaches. However, these LC-ESI platforms usually favour the detection of metabolites present at 
relatively high concentrations because of analytical limitations such as ion suppression, thus 
reducing overall sensitivity. To counter this issue of sensitivity, the latest in terms of analytical 
platforms can be adopted to enable a greater portion of the metabolome to be analysed in a single 
analytical run. Here, nanoflow liquid chromatography-nanoelectrospray ionisation (nLC-nESI), which 
has previously been utilised successfully in proteomics, is explored for use in metabolomic and 
exposomic research. As a discovery based field, the markedly increased sensitivity of these nLC-nESI 
platforms offer the potential to uncover the roles played by low abundant signalling metabolites 
(e.g. steroids, eicosanoids) in health and disease studies, and would also enable an improvement in 
the detection of xenobiotics present at trace levels in biological matrices to better characterise the 
chemical exposome. This review aims to give an insight into the advantages associated with nLC-nESI 
for metabolomics-based approaches. Initially we detail the source of improved sensitivity prior to 
reviewing the available approaches to achieving nanoflow rates and nanospray ionisation for 
metabolomics. The robustness of nLC-nESI platforms was then assessed using the literature available 
from a metabolomic viewpoint. We also discuss the challenging point of sample preparation which 
needs to be addressed to fully enjoy the benefits of these nLC-nESI platforms. Finally, we assess 
metabolomic analysis utilising nano scale platforms and look ahead to the future of metabolomics 
using these new highly sensitive platforms. 
Key words: nanoflow, nanoESI, metabolomics, exposomics, ion suppression, sample preparation 
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1. Introduction 
The aim of untargeted metabolomics is the comprehensive analysis of all known and 
unknow metabolites in a biological sample such as cells, biofluids or tissues at any one time [1]. 
Quantitative strategy can also be used where dozens to hundreds of metabolites are targeted and 
this is referred to as targeted metabolomics [2]. The metabolites in question are typically <1000 Da 
[3, 4], and are reactants, intermediates or by-products of enzymatic activity [1]. In some cases, these 
metabolites may be exogenous in source (e.g., xenobiotics), such as food additives from the diet [5], 
pharmaceutical intake (e.g. anti-inflammatory drugs and mild analgesics, antidepressants) [6, 7] or 
use of cosmetics (e.g., parabens, UV filters) [8]. The combination of the metabolome (including 
microbial metabolism) and xenobiotics as well as their products from phase I and/or II metabolism in 
biological samples is known as the (xeno)metabolome [6, 9-12]. Profiling biological samples from 
different populations such as diseased and healthy subjects or exposed and non-exposed subjects 
using an untargeted metabolomics-based approach combined with chemometric pattern analysis 
allows for the potential to simultaneously uncover biomarkers of effect (i.e. disruption of 
endogenous metabolite profiles) as well as biomarkers of exposure (i.e., xenobiotic mixtures). 
Metabolomics-based approaches has thus wide applicability in medicine [13, 14], toxicology [6, 15, 
16], food sciences [5, 17], exposomics and human health studies [12, 18, 19], plant sciences [20, 21], 
and environmental sciences [9, 22, 23].  
To undertake untargeted analysis, analytical platforms capable of analysing thousands of 
metabolites simultaneously are required. To date, the most widely used analytical platform is liquid 
chromatography-mass spectrometry (LC-MS), typically utilising an electrospray ionisation source 
(ESI) [24, 25]. These LC-ESI platforms can offer highly reproducible and very high throughput 
methods to perform untargeted profiling of biological samples for metabolomics-based approaches. 
Furthermore, the soft ionisation process of LC-ESI platforms allows structural elucidation and the 
analysis of both volatile and non-volatile metabolites. However, these LC-ESI platforms usually 
favour the detection of metabolites present at relatively high concentrations because of analytical 
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issues such as poor ionisation efficiency and ion suppression [26, 27]. This is a major limitation since 
the idea behind the use of a metabolomics-based approach is to discriminate new biomarkers of 
effect or exposure that have so far remained unidentified. It is therefore essential for these 
untargeted methods to be sensitive enough to detect signalling metabolites or xenobiotics present 
at trace levels and that could be important in health effect outcomes. There is therefore a need for 
innovative strategies which allow to overcome sensitivity issues caused by ion suppression for 
metabolomics-based approaches.  
 
As a result of these deficiencies, LC and ESI technologies have slowly been miniaturised and 
the latest developments in LC-MS have taken miniaturisation a step further with the development of 
nanoLC-nanoESI (nLC-nESI) [28, 29]. As the name suggests, flow rates are on the nL/min scale and 
has been defined as LC platforms that deliver flow rates of 10-1000 nL/min with ESI emitters internal 
diameters (ID) of between 10 and 50 µm [30, 31]. The increased sensitivity of the nLC-nESI can be 
attributed to factors derived from both the nLC and nESI source, the latter being the main source of 
the increased sensitivity. The use of nESI emitters means that the droplets formed in the ESI plume 
are 100-1000 fold smaller than the typical droplets emitted from conventional ESI emitters [32]. The 
process of ESI is an evaporative one, and therefore the generation of significantly smaller plume 
droplets with lower volumes considerably increases the rate of desolvation, resulting in up to 500 
times more ions being formed and entering the mass analyser [32-35]. Another advantage of nESI 
lies in the fact that the emitter is closer to the MS inlet compared to conventional ESI, allowing a 
more efficient introduction of the ions formed into the inlet [36]. In addition, due to the much lower 
flow rate, chromatographic dilution is significantly decreased allowing more concentrated peaks to 
elute from the analytical column [37-39]. Further advantages of the nLC-nESI include reduced 
desolvation temperature [40] and  the decrease of the consumption of both mobile and stationary 
phases [28].  
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Hence, these nano scale platforms offer a significant improvement in terms of sensitivity due 
to increased ionisation efficiency and reduced chromatographic dilution. These characteristics offer 
great potential to metabolomic researchers looking to encompass as much of the metabolome as 
possible. This review aims to give an insight to the advantages associated with nLC-nESI for 
metabolomics. To do this, we first describe the different techniques that have been used to achieve 
nLC and nESI for metabolomics. Here, we will focus on nanoscale instrumentation that have been 
successfully applied to metabolomic applications since comprehensive reviews on miniaturised 
liquid chromatography instrumentation can be found elsewhere, e.g.,[28].  We then discuss the 
robustness of these platforms in targeted analysis and global metabolomic studies. We also discuss a 
challenging point, the sample preparation, which needs to be addressed to get the most out of the 
platforms sensitivity while not adversely impacting upon the metabolomic analysis. Subsequently, 
we look ahead to the potential nLC-nESI-MS has in metabolomics for elucidating the roles played by 
very low abundance metabolites in health, disease and the potential nLC-nESI-MS has for the 
identification of mixtures of xenobiotics in exposure assessment. 
2. Overview of nLC-nESI platforms and advantages for metabolomics 
The aim of this section is to present instrumentations which can be utilised for 
metabolomics to generate nanoflow rates, the different nanocolumns and nESI emitters and to 
discuss their advantages and drawbacks. An overview of instrumentation, nanocolumns and 
methods used for metabolomics can be seen in Table 1. 
2.1 Nanoflow generation 
The method by which nanoflow rates are produced can have a dramatic effect on the quality 
of the chromatography and repeatability of the analysis, either in terms of peak shape or retention 
time. Here the generation of nanoflow rates for direct infusion metabolomics will be discussed in 
addition to the formation of nanoflow rate by splitting higher flow rates and direct from pump 
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generation for nLC-MS. These methods are known as self-fed/direct infusion, split flow, and direct 
flow, respectively.  
2.1.1 Self-fed/ direct infusion nanoESI 
While not a nLC-nESI method strictly speaking, direct infusion nESI-MS has proven popular 
for a number of metabolomic studies to analyse liver extracts [41-43], plasma [44], urine [45], 
zebrafish embryos [46], Daphnia magna [47]. These studies benefitted from the generation of 
nanoflow rates within a nESI emitter to achieve sensitive and high throughput analysis [30, 42]. 
Furthermore, direct infusion nESI reduces the volume of solvent used by 1000 fold compared to 
conventional LC-MS [48]. Self-fed systems load sample directly into an emitter to which a voltage is 
applied initiating a nanospray via capillary action and electrostatic force [33, 49, 50]. These systems 
were initially utilised in proteomics, however, they were known to offer poor reproducibility [51-53]. 
In addition, samples must be manually loaded individually into the tips and be installed for each run, 
making automated high-throughput analysis difficult [51-53].  
 New chip based methods automatically aspirate sample into a disposable tip which 
interfaces with a nESI emitter [30, 51-54]. Each tip and emitter is single use, eliminating carryover, 
reduces the impact of emitter blockage and significantly increases sample throughput [48, 52, 53, 
55, 56]. A novel method known as SIM stitch, collects direct infusion Orbitrap MS data using a series 
of overlapping SIM windows. Once collected SIM windows are “stitched” together to create a full MS 
spectra covering the entire m/z range. This technique alleviates the effect of space charge effects in 
the Orbitrap mass analyser and reduces the impact of high abundance metabolites being 
preferentially analysed [42, 57].  
The use of direct infusion nESI for high-throughput analyses seems to fit well with the 
application of metabolomics in studies which requires consecutive analysis of very large numbers of 
samples (e.g., epidemiological studies) by reducing dramatically the time and the cost of analysis. 
However, the lack of chromatographic separation in direct infusion methods means that the analysis 
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still suffers from ion suppression [48, 55]. In addition, these methods are unable to differentiate 
between isobaric/isomeric molecules or provide definitive metabolite identification without the 
need for subsequent fragmentation and/or chromatographic experiments, such as nLC-nESI-MS [56].  
2.1.2 Split flow 
When nLC was first introduced commercial pumps capable of delivering nanoflow rates were 
not available [31]. To counter this, HPLC pumps provided high flow rates which were subsequently 
split to provide nano scale flow rates with surplus mobile phase going to waste [27]. Depending 
upon where the flow is split, up to 99% of the sample can be lost, thus, eliminating the benefit of low 
volume or precious samples [36]. In addition, the green chemistry benefits are lost as most of the 
solvent goes to waste in the splitting process [31, 58]. A further complication is evident when trying 
to perform a gradient separation. Due to differing mobile phase viscosities, variation in back 
pressure and surface tension is observed, making it more difficult to achieve stable retention 
characteristics when using non-commercial flow splitters [58, 59]. One large advantage to the use of 
split flow systems is that they have a dual use as a conventional LC and a nanoflow system 
effectively giving researchers two instruments in one. The lack of split flow use in metabolomics 
potentially reflects upon the aforementioned disadvantages.  
2.1.3 Direct flow 
 In recent years, technological advances have enabled commercially available nano 
reciprocal or syringe pumps to become widely available [60]. These platforms have been called 
direct nanoflow, due to the nanoflow rates being provided directly from the LC pumps. Unlike most 
of their split flow counterparts, direct flow platforms make use of micro fluidic flow controllers 
which control flow rates much more precisely than flow split systems [61]. Furthermore, there are 
fewer connections in the system thus reducing the risk of leakages, zero dead volumes and 
blockages [61]. The use of direct nanoflow is of particular importance in analysis utilising a gradient 
system. This is due to its ability to allow for variation in mobile phase viscosities using sophisticated 
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flow controllers [58, 59]. It is known that providing nanoflow rates directly from the pump improves 
retention and spray characteristics of the nano platform [37, 58]. In addition, the cost and 
environmental benefits of reduced solvent usage are also realised using direct nanoflow pumps [58]. 
To date direct nLC has been implemented in a small number of metabolomic analysis of urine [62-
65], plasma [11], tissue [23], faeces [66], exhaled breath condensates [67], sweat [68], cerebrospinal 
fluids [69] and cell extracts [70].  
2.2 Nanocolumns 
According to the classification of Saito et al. [71], nanocolumns range from 0.01 to 0.1 mm 
internal diameter (ID). In this review, we have included metabolomic studies using nanocolumns 
with ID up to 0.2 mm but with flow rates within the nanoflow rate ranges (i.e., up to 1000 nL/min) 
(Table 1). The main advantages of columns with lower ID compared with conventional HPLC columns 
are reduced chromatographic dilution, lower consumption of mobile phases and lower consumption 
of sample mainly due to the lower flow rates [28, 72].  
Due to the broad range of physico-chemical properties of small molecules (e.g., polarity, 
size) analysed in metabolomics, it is important that as many as possible can be retained on an 
analytical column with sufficient separation between each other. Nanocolumns used in metabolomic 
studies so far include BEH C18, HSS T3, Acclaim PepMax C18 and ZIC-HILIC for a wide range of 
matrices (Table 1). It must be noted that the majority of nanocolumns available utilise conventional 
reversed phased column chemistries. However, normal phase such as HILIC are now available from 
Merck (ZIC-HILIC 75-100 µm i.d), Sciex cHiPLC (75 µm x 15cm HALO HILIC), Tosoh (TSK-GEL Amide-80 
HILIC, 50 µm i.d.) and NewObjective (Unison UK-Amino 75 µm -10 mm) which could then be used to 
improve the retention of very polar and polar metabolites for nanoscale platforms as seen in the 
sole nanoHILIC study to date [69].  
A comparative study of three reversed phase nanocolumns with two column chemistries and 
three different pore sizes (BEH C18 300 and 130 Å, and HSS T3 100 Å) was performed in view of 
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metabolomic applications for urine and plasma [73] (see Fig. 1). Increased retention, separation and 
increased peak area were observed for most of the metabolites tested with the low porosity 
columns (100 and 130 Å), due to a combination of decreased chromatographic dilution, increased 
stationary phase surface area and increased mass transfer rate [39, 73, 74]. Furthermore, the 
retention of many analytes was favoured by the HSS phase compared with the BEH, suggesting that 
the use of HSS T3 phase with porosity smaller pore size could increase the performance of the 
system by reducing co-elution and ion suppression for metabolomic applications.  
Similar phases to these used for metabolomics with conventional HPLC columns are already 
available for nanocolumns and allow to achieve a comprehensive coverage of the metabolome of 
urine [64], plasma [10] and tissues samples [23]. However, more nanocolumns adapted in terms of 
column chemistry and pore sizes (i.e. lower pore size than for proteomics) would be welcome to gain 
optimal sensitivity and chromatographic separation of polar, mid-polar and apolar metabolites for 
metabolomic analysis. 
2.3 Nano ESI sources 
A nESI source is characterised by the narrow bore nanospray emitter. The sensitivity and 
reproducibility of nESI analysis is directly related to the quality of the emitter [75, 76]. Several factors 
such as the emitter material, tip geometry and the internal diameter influence the quality of nESI 
emitters [49, 75, 77]. For metabolomic applications, metal emitter may provide the most robust 
qualities and can be cleaned thus reducing costs associated with replacing damaged or blocked 
emitters [75, 78]. It is worth noting that homemade emitters can be constructed and these are 
generally less expensive that commercial ones. The geometry of the emitter is an important 
consideration for small molecule analysis as it impacts upon spray stability and emitter longevity. 
The use of tapered emitters has been demonstrated to have a shorter usable lifetime than non-
tapered tips, mainly as a result of clogging [77]. In other studies, tapered emitters have been found 
to produce a more stable nanospray, meaning that more reproducible mass spectra can be produced 
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[75, 76]. The internal diameter of the emitter is a further source of increased ionisation efficiency of 
the nESI source. A study by Lopes et al. [75] investigated 4 internal diameters; 5, 10, 20 and 30 µm 
and found that all emitters had similar sensitivity in terms of spectral features and total ion current. 
However, it was determined that the 30 µm was preferred as clogging is less frequent due to the 
larger orifice [75]. In other studies, the smaller the internal diameter, the greater the observed 
ionisation efficiency, however, emitter clogging became problematic at internal diameters below 10 
µm [79].  
With these factors considered, the use of non-tapered emitters with an internal diameter in 
the range of 10-30 µm offers an acceptable compromise between sensitivity, system longevity and 
potential loss of sample.  
3. Robustness of nanoflow platforms for metabolomics 
In metabolomics, the ability to generate highly repeatable and reliable data is a key factor to 
ensure high quality studies can be carried out [80, 81]. Two major sources of variation that limit the 
quality of metabolomic data sets are retention time drift and poor peak intensity reproducibility [80, 
82]. The stability of retention time in particular is of great significance during the peak picking 
process prior to multivariate statistical analysis. To date, many studies have reported on retention 
time and mean peak area repeatability while analysing a broad range of compounds and matrices. 
While many of these have been in targeted approaches they provide a good indication as to the 
suitability for untargeted small molecule analysis.  
3.1 Retention time stability 
For metabolomic analysis, it has been suggested that the % coefficient of variation (%CV) for 
retention time should not exceed 2% [24]. The retention time variation reported in studies using 
both direct and split nanoflow systems for small molecule analysis in targeted and untargeted 
studies are detailed in Table 2. The range of CVs reported was lower with direct nanoflow systems 
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(<0.20% to 2.2%) than for split flow ones (0.50-3.4%). Furthermore, all reported CVs were below the 
2% threshold with direct nanoflow systems (with the exception of the 2D nLC system) and usually 
lower than 1% (in 12 out of 19 studies). On the other hand, 3 out 13 reported CVs were higher than 
the 2% threshold for the split flow and these systems typically have CVs greater than 1% (in 9 out of 
13 studies). Overall, these studies reported highly reproducible results for retention times but seems 
to highlight the importance of pump fed direct nanoflow for retention time stability [24].  
The number of metabolomic studies reporting retention time stability for nanoflow 
platforms is very limited. To date, only two have reported retention time stability of metabolites [11, 
62]. In both studies, the CV was below 1.9%. A further metabolomics study has reported the 
retention time stability of 6 internal standards, and CVs below 0.2% were reported for these internal 
standards spiked in plasma and urine [73]. 
Comparing retention time repeatability reported in different studies is quite difficult 
because of differences in chromatographic methods (e.g. solvents, additives such as formic acid) and 
matrices used for the experiment. Nevertheless, the reported CVs for the split and direct nanoflow 
platforms suggest that reproducible retention characteristics are achievable on both nanoflow 
systems even if direct nanoflow provides slightly more retention time reproducibility.  
3.2 NanoESI MS response stability 
It has been suggested that a CV of up to 30% is acceptable for variation of mean peak area in 
metabolomics analysis [83]. The mean peak CV has been reported in a number of studies using 
nanoflow systems, covering a wide range of analytes and samples matrices (Table 3).  
Overall, these targeted and untargeted studies indicate that a high degree of peak area 
reproducibility can be achieved since CV of peak area calculated for a wide range of metabolites 
were lower than 20% in all but one study. There appears to be little difference between emitter 
geometry and internal diameters for those studies, showing that no single diameter or geometry 
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appeared preferential in terms of reproducibility for these studies. The low reproducibility reported 
by Kiefer et al. [84] may be due to the fact that ion pairing solvents were in use which can be less 
stable in the ESI source. Moreover, this was reported for only 1 compound (all others being below 
14%). While these studies investigated only a limited number of compounds, they demonstrate that 
nLC-nESI is reproducible in terms of peak area. 
As with retention time stability, the mean peak area reproducibility in metabolomic analysis 
has only been investigated in a small number of cases. In these cases the variation in mean peak 
areas for the whole metabolome were investigated using either the method or a modification of the 
method proposed by Want et al. [83]. In all these studies, >70% peaks of quality control samples 
returned CV of <30% for negative and positive nESI respectively [11, 62-64]. Furthermore, Jones et 
al. reported that >50% of all peaks measure in the metabolome of yeast cell extracts had a CV of < 
14% [70]. Each of these studies indicates that the reproducibility of the nESI source is capable of 
supplying reliable results for metabolomics. 
4. Sample preparation strategies for metabolomic studies using nLC-nESI 
Sample preparation is an important aspect to consider for the use of nanoflow platforms for 
metabolomics [11, 73, 85]. The narrow bore columns, emitters and connections are prone to 
blockages and consequently, efficient sample clean-up are recommended to remove particulates, 
salts and proteins [11]. In the field of untargeted metabolomics, it has often been argued that 
selective sample preparation such as solid phase extraction (SPE) should be avoided in order to have 
the whole picture of the sample. However, several studies have shown that sample preparation 
based on SPE can increase the coverage of the metabolome compared with conventional protein 
precipitation (PPT) as well as the repeatability of the method [11, 86-88].  
 Sample preparation for metabolomic purposes that allow for the efficient removal of 
interfering matrix components other than PPT include, for instance, offline or online SPE, solid-phase 
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microextraction (SPME), ultrafiltration, delipidation using commercially available lipid depletion 
plate and Quick, Easy, Cheap, Effective, Rugged and Safe (QuEChERS) methods [11, 25, 87, 89-92]. 
These techniques can be used on their own or in combination with other techniques such as LLE, 
with or without fractionation [93]. Among these different techniques, delipidation (mainly lyso- and 
phospholipids) of the sample has gained increased interest because it can reduce ion-suppression 
effects and can increase column lifetime [11, 90]. These recent innovations are effective for 
removing phospholipids and they have been shown, in combination to solvent deproteinisation, to 
enhance analyte detection of non-lipid species in comparison to extractions with organic solvents 
and a membrane-based solvent free technique [87]. It is also worth noting that miniaturised sample 
preparation techniques such as SPME [94], stir bar sorptive extraction (SBSE) [95]or microextraction 
by packed sorbent (MEPS) [96] may be applied to nanoscale LC, and applications in metabolomic 
studies are numerous in the case of SPME [94, 97]. 
Examples of applications of these sample preparation techniques in metabolomics-based 
approaches using a nLC-nESI system include a study where plasma samples were extracted using 
phospholipid filtration plates in combination with polymeric or mixed mode exchange SPE [11]. 
Another study described a SPE methodology to enable a high urine equivalence to be injected on a 
nLC-nESI-MS platform [62]. Additionally, lyophilisation and SPE has been used to prepare yeast 
samples for metabolomic analysis using a nLC-nESI-MS platform [70]. These studies showed that 
injections of more concentrated extracts onto nLC-nESI-MS platforms using more selective sample 
preparation can result in a wider coverage of the metabolome and can also extend the column life 
time. 
In addition, column trapping has also been used in metabolomics-based approaches using a 
nLC-nESI system to load a larger volume of sample. While the metabolites are “trapped”, mobile 
phase continues to wash through the column thus removing any salts and any other unretained 
contaminants [68]. This method can be used to replace offline SPE and automate the entire sample 
preparation and analysis process [98]. 
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5. Current and potential use of nLC-nESI in metabolomics 
Although still limited, several papers have already used nLC-nESI-MS platforms in 
metabolomics. These studies have highlighted that these systems may be up to 2000 fold more 
sensitive than conventional LC-ESI-MS [73] and with LOD and LOQs up to 300 fold lower using nLC-
nESI-MS [85]. Two studies have also shown how nLC-nESI-MS can be combined with chemical 
isotope labelling to further increase the coverage of the metabolome and enhance the relative 
quantification of metabolites [68, 98].  In this section, we review the different studies which have 
used nLC-nESI-MS systems in metabolomics according to their applications. 
5.1 Health and disease metabolomics 
The prospect of very highly sensitive analysis of low abundance or difficult to ionise 
metabolite species provides an exciting prospect for metabolomic studies of health and disease. 
Metabolic pathways of particular interest are, for instance, conjugated and unconjugated sex 
steroids such as the estrogens and androgens which are implicated in several cancers, infertility and 
other related endocrine disruption problems [99]. These metabolites are typically found at low 
concentrations and usually difficult to ionise using conventional ESI-MS. Also of interest and found at 
low concentrations are metabolites involved in inflammation and several disease pathways such as 
eicosanoids [100].  
A couple of early metabolomics-based studies investigated the effect of dietary compounds 
on health and disease using nLC-nESI-MS. In one study, the potential for phenol rich olive oil was 
investigated for its cell proliferation inhibition capacity in colon cancer [101]. The other nutraceutical 
investigation using nLC-nESI-MS was implemented to investigate the health benefits associated with 
the consumption of citrus juice [65]. In this study, significant changes in steroidogenesis pathways 
were detected following citrus juice consumption. Some of the detected steroids, in particular 17-
hydroxyprogesterone, are typically found at low levels in urine, thus requiring a highly sensitive 
analysis to detect these changes.  
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In human health and disease, four studies using nLC-nESI-MS have been carried out to date, 
one on HIV [64], one on drug resistant multiple myeloma [70], a third on paediatric spondylarthrosis 
[66] and the most recent investigating lung disease in new-born neonates [67]. The metabolomic 
analysis of anti-retroviral toxicity in the urine of HIV positive patients detected for the first time all 
the anti-retroviral drugs and a wide range of their metabolites in addition to several low abundance 
endogenous metabolites in an untargeted analysis (see Fig. 2 for example of chromatograms) [64]. 
The most recent study investigated exhaled breath condensates from two lung morphologies in 
intubated neonates (<20 days old). The ability to analyse samples such as exhaled breath 
condensates requires a highly sensitive technique due to the low volumes available. Concentrations 
of a number eicosanoids were found to differentiate between the control group and the diseased 
lung groups highlighting an inflammatory aspect of the conditions [67]. Furthermore, eicosanoids 
were detected in 60% of all samples underlying the sensitivity of the nLC-nESI-MS approach used as 
previous analysis has shown these compounds are present at a pg/mL level in exhaled breath 
condensates [67, 102].  
An example of application using targeted metabolomics includes a study where a sensitive 
nLC-nESI-MS method was developed to monitor 184 phosphorus-related metabolic changes in small 
volumes of cancer cells treated with metabolic enzyme inhibitors [103].  
These studies indicate that nLC-nESI-MS platforms are well suited for metabolomic analysis 
in health and disease studies. Using nLC-nESI-MS to uncover low abundance signalling metabolites, it 
may become possible to characterise unique metabolites and metabolic pathways affected in 
different cancers and diseases. 
5.2 Exposure assessment and biomonitoring studies 
With regards to the very high diversity of xenobiotics present in the environment, 
metabolomics-based approaches using highly sensitive nLC-nESI platforms offer exciting 
perspectives to detect xenobiotic mixtures (i.e., the chemical exposome), usually present at trace 
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levels, in environmental and biological samples and simultaneously study their potential associated 
health effects [104, 105].  
To date, the use of nLC-nESI-MS platforms in untargeted analysis for exposure assessment 
has been very limited. It includes a study in which a metabolomics-based approach using a nUPLC-
nESI-TOFMS platform was used to investigate the chemical mixtures accumulating in fish exposed to 
a treated wastewater effluent and the associated changes in the tissues metabolome [23]. A wide 
range of contaminants including 31 pharmaceuticals from 11 different classes, endocrine disrupters, 
personal care products, pesticides, antibacterials and human dietary products were detected, 
sometimes at very low concentrations, in blood plasma and tissues of effluent-exposed fish (see Fig. 
3 for example of chromatograms). Concurrently, metabolite profiling revealed for the first time a 
widespread reduction (between 50% and 90%) in prostaglandin (E2 and F2α) profiles in effluent-
exposed fish tissues/plasma [23]. Another example of application using nLC platform for exposure 
assessment includes a study where an untargeted approach was used to investigate changes in a 
small benthic invertebrates exposed to a wastewater treatment plant effluent. Significant changes in 
lipid metabolism were observed and several xenobiotics were detected (e.g., ibuprofen and 
propranolol) in invertebrates exposed to the wastewater treatment plant effluent using very small 
invertebrate samples (i.e., 12 mg) [92]. 
These studies show that highly sensitive untargeted techniques based on nanoscale could be 
extremely useful to identify xenobiotics that need to be prioritised for future toxicological 
investigations.  
6. Conclusions and future perspectives 
 The current literature surrounding nLC-nESI clearly demonstrates that significant gains in 
sensitivity for metabolites can be achieved compared to conventional LC-ESI platforms (see Table 4 
for a summary of advantages and drawbacks of nLC-nESI platforms). While in the past there has 
18 
 
been concern about nLC retention time reproducibility, the review of existing data shows that the 
improvements made since the introduction of nanoflow, such as the implementation of direct 
nanoflow platforms, have greatly contributed to improve the reproducibility of these platforms since 
the majority of these studies fall within the guidelines proposed within the metabolomic community. 
As mentioned in this review, one key factor is sample preparation, which is required to extend 
column and emitter lifetimes by reducing blockages. While this process is indeed more time 
consuming and may be seen as selective, several studies have shown that more extensive sample 
preparation can increase the coverage of the metabolome as it allows injection of more 
concentrated extracts and, on the other hand, improve the repeatability of the method. Hence, 
more automated sample preparation methods should be developed in the future to implement 
metabolomic methods based on nLC-nESI platforms for high throughput applications. Taking the 
current nLC-nESI methods and potential future advances into account, new and exciting possibilities 
exist to expand impact of metabolomics on human and environmental health and disease. The 
increased sensitivity of these nLC-nESI platforms offer the potential to uncover the roles played by 
low abundant signalling metabolites in health and disease studies, and would also enable an 
improvement in the detection of xenobiotics present at trace levels in biological matrices to better 
characterise the chemical exposome and uncover potential health outcomes associated. While many 
aspects of metabolomics are still under progress (e.g., development of more automated annotation 
work-flows to overcome problems linked to unidentified features), the development of analytical 
methods of higher sensitivity is also a priority to be as comprehensive as possible. 
Acknowledgment 
AC received funding from the EPSRC and University of Sussex as part of his PhD. AD was 
supported by a Marie Curie Intra European Fellowship within the European Community Seventh 
Framework Programme ([FP7/2007-2013]) under grant agreement no: 302097. 
19 
 
References 
[1] W.B. Dunn, D.I. Broadhurst, H.J. Atherton, R. Goodacre, J.L. Griffin, Systems level studies of 
mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance 
spectroscopy, Chem. Soc. Rev. 40(1) (2011) 387-426. 
[2] W. Lu, B.D. Bennett, J.D. Rabinowitz, Analytical strategies for LC-MS-based targeted 
metabolomics, J Chromatogr B Analyt Technol Biomed Life Sci 871(2) (2008) 236-42. 
[3] J.K. Nicholson, Global systems biology, personalized medicine and molecular epidemiology, Mol. 
Syst. Biol. 2 (2006) 1-6. 
[4] P.A. Guy, I. Tavazzi, S.J. Bruce, Z. Ramadan, S. Kochhar, Global metabolic profiling analysis on 
human urine by UPLC-TOFMS: Issues and method validation in nutritional metabolomics, J. 
Chromatogr. B 871(2) (2008) 253-260. 
[5] A. Scalbert, L. Brennan, C. Manach, C. Andres-Lacueva, L.O. Dragsted, J. Draper, S.M. Rappaport, 
J.J.J. van der Hooft, D.S. Wishart, The food metabolome: a window over dietary exposure, Am. J. Clin. 
Nutr. 99(6) (2014) 1286-1308. 
[6] C.H. Johnson, A.D. Patterson, J.R. Idle, F.J. Gonzalez, Xenobiotic Metabolomics: Major Impact on 
the Metabolome, Annu. Rev. Pharmacol. Toxicol. 52 (2012) 37-56. 
[7] D.M. Kristensen, S. Mazaud-Guittot, P. Gaudriault, L. Lesne, T. Serrano, K.M. Main, B. Jegou, 
Analgesic use - prevalence, biomonitoring and endocrine and reproductive effects, Nat Rev 
Endocrinol 12(7) (2016) 381-93. 
[8] I. Jiménez-Díaz, A. Zafra-Gómez, O. Ballesteros, A. Navalón, Analytical methods for the 
determination of personal care products in human samples: An overview, Talanta 129(0) (2014) 448-
458. 
[9] R. Al-Salhi, A. Abdul-Sada, A. Lange, C.R. Tyler, E.M. Hill, The Xenometabolome and Novel 
Contaminant Markers in Fish Exposed to a Wastewater Treatment Works Effluent, Environ. Sci. 
Technol. 46(16) (2012) 9080-9088. 
[10] E. Holmes, R.L. Loo, O. Cloarec, M. Coen, H.R. Tang, E. Maibaum, S. Bruce, Q. Chan, P. Elliott, J. 
Stamler, I.D. Wilson, J.C. Lindon, J.K. Nicholson, Detection of urinary drug metabolite 
(Xenometabolome) signatures in molecular epidemiology studies via statistical total correlation 
(NMR) spectroscopy, Anal. Chem. 79(7) (2007) 2629-2640. 
[11] A. David, A. Abdul-Sada, A. Lange, C.R. Tyler, E.M. Hill, A new approach for plasma 
(xeno)metabolomics based on solid-phase extraction and nanoflow liquid chromatography-
nanoelectrospray ionisation mass spectrometry, J Chromatogr A 1365 (2014) 72-85. 
[12] P. Vineis, M. Chadeau-Hyam, H. Gmuender, J. Gulliver, Z. Herceg, J. Kleinjans, M. Kogevinas, S. 
Kyrtopoulos, M. Nieuwenhuijsen, D.H. Phillips, N. Probst-Hensch, A. Scalbert, R. Vermeulen, C.P. 
Wild, The exposome in practice: Design of the EXPOsOMICS project, Int. J. Hyg. Environ. Health 220 
(2017) 142-151. 
[13] J. Balog, L. Sasi-Szabó, J. Kinross, M.R. Lewis, L.J. Muirhead, K. Veselkov, R. Mirnezami, B. Dezső, 
L. Damjanovich, A. Darzi, J.K. Nicholson, Z. Takáts, Intraoperative Tissue Identification Using Rapid 
Evaporative Ionization Mass Spectrometry, Sci. Transl. Med. 5(194) (2013) 194ra93. 
[14] S. Medina, R. Dominguez-Perles, J.I. Gil, F. Ferreres, A. Gil-Izquierdo, Metabolomics and the 
Diagnosis of Human Diseases - A Guide to the Markers and Pathophysiological Pathways Affected, 
Curr. Med. Chem. 21(7) (2014) 823-848. 
[15] N. Bonvallot, M. Tremblay-Franco, C. Chevrier, C. Canlet, L. Debrauwer, J.P. Cravedi, S. Cordier, 
Potential Input From Metabolomics for Exploring and Understanding the Links Between 
Environment and Health, J Toxicol Environ Health B Crit Rev 17(1) (2014) 21-44. 
[16] M. Bouhifd, T. Hartung, H.T. Hogberg, A. Kleensang, L. Zhao, Review: Toxicometabolomics, J. 
Appl. Toxicol. 33(12) (2013) 1365-1383. 
[17] C. Ibanez, A. Valdes, V. Garcia-Canas, C. Simo, M. Celebier, L. Rocamora-Reverte, A. Gomez-
Martinez, M. Herrero, M. Castro-Puyana, A. Segura-Carretero, E. Ibanez, J.A. Ferragut, A. Cifuentes, 
Global Foodomics strategy to investigate the health benefits of dietary constituents, J. Chromatogr. 
A 1248 (2012) 139-153. 
20 
 
[18] E.L. Jamin, N. Bonvallot, M. Tremblay-Franco, J.P. Cravedi, C. Chevrier, S. Cordier, L. Debrauwer, 
Untargeted profiling of pesticide metabolites by LC-HRMS: an exposomics tool for human exposure 
evaluation, Anal. Bioanal. Chem. 406(4) (2014) 1149-1161. 
[19] N. Bonvallot, A. David, F. Chalmel, C. Chevrier, S. Cordier, J.-P. Cravedi, D. Zalko, Metabolomics 
as a powerful tool to decipher the biological effects of environmental contaminants in humans, 
Current Opinion in Toxicology 8 (2018) 48-56. 
[20] O. Fiehn, Metabolomics - the link between genotypes and phenotypes, Plant Mol. Biol. 48(1-2) 
(2002) 155-171. 
[21] L.W. Sumner, P. Mendes, R.A. Dixon, Plant metabolomics: large-scale phytochemistry in the 
functional genomics era, Phytochemistry 62(6) (2003) 817-836. 
[22] M. Viant, U. Sommer, Mass spectrometry based environmental metabolomics: a primer and 
review, Metabolomics 9(1) (2013) 144-158. 
[23] A. David, A. Lange, A. Abdul-Sada, C.R. Tyler, E.M. Hill, Disruption of the Prostaglandin 
Metabolome and Characterization of the Pharmaceutical Exposome in Fish Exposed to Wastewater 
Treatment Works Effluent As Revealed by Nanoflow-Nanospray Mass Spectrometry-Based 
Metabolomics, Environ Sci Technol 51(1) (2017) 616-624. 
[24] G.A. Theodoridis, H.G. Gika, E.J. Want, I.D. Wilson, Liquid chromatography-mass spectrometry 
based global metabolite profiling: A review, Anal. Chim. Acta 711 (2012) 7-16. 
[25] H.G. Gika, G.A. Theodoridis, R.S. Plumb, I.D. Wilson, Current practice of liquid chromatography-
mass spectrometry in metabolomics and metabonomics, J. Pharm. Biomed. Anal. 87(18) (2014) 12-
25. 
[26] J.P. Antignac, K. de Wasch, F. Monteau, H. De Brabander, F. Andre, B. Le Bizec, The ion 
suppression phenomenon in liquid chromatography–mass spectrometry and its consequences in the 
field of residue analysis, Analytica Chimica Acta 529 (2005) 129-36. 
[27] T.O. Metz, J.S. Page, E.S. Baker, K. Tang, J. Ding, Y. Shen, R.D. Smith, High Resolution Separations 
and Improved Ion Production and Transmission in Metabolomics, Trends Analyt Chem 27(3) (2008) 
205-214. 
[28] C.E. Nazario, M.R. Silva, M.S. Franco, F.M. Lancas, Evolution in miniaturized column liquid 
chromatography instrumentation and applications: An overview, J Chromatogr A 1421 (2015) 18-37. 
[29] L.E. Blue, E.G. Franklin, J.M. Godinho, J.P. Grinias, K.M. Grinias, D.B. Lunn, S.M. Moore, Recent 
advances in capillary ultrahigh pressure liquid chromatography, J Chromatogr A 1523 (2017) 17-39. 
[30] E.R. Wickremsinhe, G. Singh, B.L. Ackermann, T.A. Gillespie, A.K. Chaudhary, A review of 
nanoelectrospray ionization applications for drug metabolism and pharmacokinetics, Curr. Drug 
Metab. 7(8) (2006) 913-28. 
[31] J.P. Chervet, M. Ursem, J.P. Salzmann, Instrumental requirements for nanoscale liquid 
chromatography, Anal. Chem. 68(9) (1996) 1507-1512. 
[32] M. Wilm, M. Mann, Analytical properties of the nanoelectrospray ion source, Anal Chem 68(1) 
(1996) 1-8. 
[33] I. Marginean, K. Tang, R.D. Smith, R.T. Kelly, Picoelectrospray ionization mass spectrometry 
using narrow-bore chemically etched emitters, Journal of the American Society for Mass 
Spectrometry 25(1) (2014) 30-36. 
[34] M. Karas, U. Bahr, T. Dulcks, Nano-electrospray ionization mass spectrometry: addressing 
analytical problems beyond routine, Fresenius J Anal Chem 366(6-7) (2000) 669-76. 
[35] I. Marginean, R.T. Kelly, D.C. Prior, B.L. LaMarche, K. Tang, R.D. Smith, Analytical 
characterization of the electrospray ion source in the nanoflow regime, Anal Chem 80(17) (2008) 
6573-9. 
[36] R.D. Smith, Y. Shen, K. Tang, Ultrasensitive and Quantitative Analyses from Combined 
Separations−Mass Spectrometry for the Characterization of Proteomes, Acc. Chem. Res. 37(4) (2004) 
269-278. 
[37] M.R. Gama, C.H. Collins, C.B.G. Bottoli, Nano-Liquid Chromatography in Pharmaceutical and 
Biomedical Research, J. Chromatogr. Sci. 51(7) (2013) 694-703. 
21 
 
[38] S. Fanali, Z. Aturki, G. D'Orazio, A. Rocco, Separation of basic compounds of pharmaceutical 
interest by using nano-liquid chromatography coupled with mass spectrometry, J. Chromatogr. A 
1150(1-2) (2007) 252-8. 
[39] M. Hilhorst, C. Briscoe, N. van de Merbel, Sense and nonsense of miniaturized LC–MS/MS for 
bioanalysis, Bioanalysis 6(24) (2014) 3263-3265. 
[40] J.S. Page, R.T. Kelly, K. Tang, R.D. Smith, Ionization and Transmission Efficiency in an 
Electrospray Ionization–Mass Spectrometry Interface, J. Am. Soc. Mass Spectrom. 18(9) (2007) 1582-
1590. 
[41] X. Shi, B. Wahlang, X. Wei, X. Yin, K.C. Falkner, R.A. Prough, S.H. Kim, E.G. Mueller, C.J. McClain, 
M. Cave, X. Zhang, Metabolomic Analysis of the Effects of Polychlorinated Biphenyls in Non-alcoholic 
Fatty Liver Disease, J. Proteome Res. 11(7) (2012) 3805-3815. 
[42] A.D. Southam, T.G. Payne, H.J. Cooper, T.N. Arvanitis, M.R. Viant, Dynamic range and mass 
accuracy of wide-scan direct infusion nanoelectrospray Fourier transform ion cyclotron resonance 
mass spectrometry-based metabolomics increased by the spectral stitching method, Anal. Chem. 
79(12) (2007) 4595-4602. 
[43] H. Wu, A.D. Southam, A. Hines, M.R. Viant, High-throughput tissue extraction protocol for NMR- 
and MS-based metabolomics, Anal. Biochem. 372(2) (2008) 204-212. 
[44] K.O. Boernsen, S. Gatzek, G. Imbert, Controlled protein precipitation in combination with chip-
based nanospray infusion mass spectrometry. An approach for metabolomics profiling of plasma, 
Anal. Chem. 77(22) (2005) 7255-64. 
[45] E. Chekmeneva, G. dos Santos Correia, Q. Chan, A. Wijeyesekera, A. Tin, J.H. Young, P. Elliott, 
J.K. Nicholson, E. Holmes, Optimization and Application of Direct Infusion Nanoelectrospray HRMS 
Method for Large-Scale Urinary Metabolic Phenotyping in Molecular Epidemiology, J. Proteome Res. 
16(4) (2017) 1646-1658. 
[46] R.-J. Raterink, F. van der Kloet, J. Li, N. Wattel, M. Schaaf, H. Spaink, R. Berger, R. Vreeken, T. 
Hankemeier, Rapid metabolic screening of early zebrafish embryogenesis based on direct infusion-
nanoESI-FTMS, Metabolomics 9(4) (2013) 864-873. 
[47] N. Taylor, R.M. Weber, A. Southam, T. Payne, O. Hrydziuszko, T. Arvanitis, M. Viant, A new 
approach to toxicity testing in Daphnia magna: application of high throughput FT-ICR mass 
spectrometry metabolomics, Metabolomics 5(1) (2009) 44-58. 
[48] J.-M. Dethy, B.L. Ackermann, C. Delatour, J.D. Henion, G.A. Schultz, Demonstration of Direct 
Bioanalysis of Drugs in Plasma Using Nanoelectrospray Infusion from a Silicon Chip Coupled with 
Tandem Mass Spectrometry, Anal. Chem. 75(4) (2003) 805-811. 
[49] M.M. Rahman, K. Hiraoka, L.C. Chen, Realizing nano electrospray ionization using disposable 
pipette tips under super atmospheric pressure, Analyst 139(3) (2014) 610-617. 
[50] A.B. Kanu, B.S. Kumar, H.H. Hill, Evaluation of micro-versus nano-electrospray ionization for 
ambient pressure ion mobility spectrometry, Int J Ion Mobil Spectrom 15(1) (2012) 9-20. 
[51] S. Zhang, C.K. Van Pelt, Chip-based nanoelectrospray mass spectrometry for protein 
characterization, Expert Rev Proteomics 1(4) (2004) 449-68. 
[52] S. Zhang, C.K. Van Pelt, J.D. Henion, Automated chip-based nanoelectrospray-mass 
spectrometry for rapid identification of proteins separated by two-dimensional gel electrophoresis, 
Electrophoresis 24(21) (2003) 3620-32. 
[53] C. Van Pelt, S. Zhang, J. Henion, Characterization of a fully automated nanoelectrospray system 
with mass spectrometric detection for proteomic analyses, J Biomol Tech 13(2) (2002) 72-84. 
[54] C.K. Van Pelt, S. Zhang, E. Fung, I. Chu, T. Liu, C. Li, W.A. Korfmacher, J. Henion, A fully 
automated nanoelectrospray tandem mass spectrometric method for analysis of Caco-2 samples, 
Rapid Commun. Mass Spectrom. 17(14) (2003) 1573-1578. 
[55] C.E. Hop, Y. Chen, L.J. Yu, Uniformity of ionization response of structurally diverse analytes using 
a chip-based nanoelectrospray ionization source, Rapid Commun. Mass Spectrom. 19(21) (2005) 
3139-42. 
22 
 
[56] E. Chekmeneva, G. Correia, J. Dénes, M. Gómez-Romero, A. Wijeyesekera, D.R. Perenyi, Y. Koot, 
C. Boomsma, E.J. Want, P.H. Dixon, Development of nanoelectrospray high resolution isotope 
dilution mass spectrometry for targeted quantitative analysis of urinary metabolites: application to 
population profiling and clinical studies, Analytical Methods 7(12) (2015) 5122-5133. 
[57] A.D. Southam, R.J.M. Weber, J. Engel, M.R. Jones, M.R. Viant, A complete workflow for high-
resolution spectral-stitching nanoelectrospray direct-infusion mass-spectrometry-based 
metabolomics and lipidomics, Nat. Protocols 12(2) (2016) 255-273. 
[58] J. Hernandez-Borges, Z. Aturki, A. Rocco, S. Fanali, Recent applications in nanoliquid 
chromatography, J. Sep. Sci. 30(11) (2007) 1589-1610. 
[59] G.A. Valaskovic, J.P. Murphy, M.S. Lee, Automated orthogonal control system for electrospray 
ionization, J. Am. Soc. Mass Spectrom. 15(8) (2004) 1201-1215. 
[60] J. Šesták, D. Moravcová, V. Kahle, Instrument platforms for nano liquid chromatography, J. 
Chromatogr. A 1421 (2015) 2-17. 
[61] M. Noga, F. Sucharski, P. Suder, J. Silberring, A practical guide to nano-LC troubleshooting, J. 
Sep. Sci. 30(14) (2007) 2179-2189. 
[62] A.J. Chetwynd, A. Abdul-Sada, E.M. Hill, Solid phase extraction and splitless nanoflow liquid 
chromatography – nanoelectrospray ionisation mass spectrometry for improved global urine 
metabolomics, Anal. Chem. 87(2) (2015) 1158-1165. 
[63] A.J. Chetwynd, A. Abdul-Sada, S.G. Holt, E.M. Hill, Use of a pre-analysis osmolality normalisation 
method to correct for variable urine concentrations and for improved metabolomic analyses, J. 
Chromatogr. A 1431 (2016) 103-110. 
[64] A.J. Chetwynd, A. Samarawickrama, J.H. Vera, S.A. Bremner, A. Abdul-Sada, Y. Gilleece, S.G. 
Holt, E.M. Hill, Nanoflow-Nanospray Mass Spectrometry Metabolomics Reveals Disruption of the 
Urinary Metabolite Profiles of HIV-Positive Patients on Combination Antiretroviral Therapy, JAIDS J. 
Acquired Immune Defic. Syndromes 74(2) (2017) e45-e53. 
[65] S. Medina, F. Ferreres, C. Garcia-Viguera, M.N. Horcajada, J. Orduna, M. Saviron, G. Zurek, J.M. 
Martinez-Sanz, J.I. Gil, A. Gil-Izquierdo, Non-targeted metabolomic approach reveals urinary 
metabolites linked to steroid biosynthesis pathway after ingestion of citrus juice, Food Chemistry 
136(2) (2013) 938-946. 
[66] M.L. Stoll, R. Kumar, E.J. Lefkowitz, R.Q. Cron, C.D. Morrow, S. Barnes, Fecal metabolomics in 
pediatric spondyloarthritis implicate decreased metabolic diversity and altered tryptophan 
metabolism as pathogenic factors, Genes Immun 17(7) (2016) 400-405. 
[67] A.S. Kononikhin, N.L. Starodubtseva, V.V. Chagovets, A.Y. Ryndin, A.A. Burov, I.A. Popov, A.E. 
Bugrova, R.A. Dautov, A.O. Tokareva, Y.L. Podurovskaya, O.V. Ionov, V.E. Frankevich, E.N. Nikolaev, 
G.T. Sukhikh, Exhaled breath condensate analysis from intubated newborns by nano-HPLC coupled 
to high resolution MS, J. Chromatogr. B 1047  97-105. 
[68] Z. Li, J. Tatlay, L. Li, Nanoflow LC-MS for High-Performance Chemical Isotope Labeling 
Quantitative Metabolomics, Anal Chem 87(22) (2015) 11468-74. 
[69] K.T. Myint, K. Aoshima, S. Tanaka, T. Nakamura, Y. Oda, Quantitative profiling of polar cationic 
metabolites in human cerebrospinal fluid by reversed-phase nanoliquid chromatography/mass 
spectrometry, Anal Chem 81(3) (2009) 1121-9. 
[70] D.R. Jones, Z.P. Wu, D. Chauhan, K.C. Anderson, J.M. Peng, A Nano Ultra-Performance Liquid 
Chromatography-High Resolution Mass Spectrometry Approach for Global Metabolomic Profiling 
and Case Study on Drug-Resistant Multiple Myeloma, Anal. Chem. 86(7) (2014) 3667-3675. 
[71] Y. Saito, K. Jinno, T. Greibrokk, Capillary columns in liquid chromatography: between 
conventional columns and microchips, J Sep Sci 27(17-18) (2004) 1379-90. 
[72] D.A. Collins, E.P. Nesterenko, B. Paull, Porous layer open tubular columns in capillary liquid 
chromatography, Analyst 139(6) (2014) 1292-302. 
[73] A.J. Chetwynd, A. David, A. Abdul-Sada, E.M. Hill, Evaluation of analytical performance and 
reliability of direct nanoLC-nanoESI-high resolution mass spectrometry for profiling the 
(xeno)metabolome, J. Mass Spectrom. 49(10) (2014) 1063-1069. 
23 
 
[74] M. Motokawa, H. Kobayashi, N. Ishizuka, H. Minakuchi, K. Nakanishi, H. Jinnai, K. Hosoya, T. 
Ikegami, N. Tanaka, Monolithic silica columns with various skeleton sizes and through-pore sizes for 
capillary liquid chromatography, J. Chromatogr. A 961(1) (2002) 53-63. 
[75] F. Lopes, D.A. Cowan, M. Thevis, A. Thomas, M.C. Parkin, Quantification of intact human insulin-
like growth factor-I in serum by nano-ultrahigh-performance liquid chromatography/tandem mass 
spectrometry, Rapid Commun. Mass Spectrom. 28(13) (2014) 1426-1432. 
[76] G.T.T. Gibson, S.M. Mugo, R.D. Oleschuk, Nanoelectrospray emitters: Trends and perspective, 
Mass Spectrom. Rev. 28(6) (2009) 918-936. 
[77] R.T. Kelly, J.S. Page, Q. Luo, R.J. Moore, D.J. Orton, K. Tang, R.D. Smith, Chemically etched open 
tubular and monolithic emitters for nanoelectrospray ionization mass spectrometry, Anal. Chem. 
78(22) (2006) 7796-801. 
[78] W. Shui, Y. Yu, X. Xu, Z. Huang, G. Xu, P. Yang, Micro-electrospray with stainless steel emitters, 
Rapid Commun. Mass Spectrom. 17(14) (2003) 1541-1547. 
[79] W. Xiong, J. Glick, Y. Lin, P. Vouros, Separation and Sequencing of Isomeric Oligonucleotide 
Adducts Using Monolithic Columns by Ion-Pair Reversed-Phase Nano-HPLC Coupled to Ion Trap Mass 
Spectrometry, Anal. Chem. 79(14) (2007) 5312-5321. 
[80] H.P. Benton, E. Want, H.C. Keun, A. Amberg, R.S. Plumb, F. Goldfain-Blanc, B. Walther, M.D. 
Reily, J.C. Lindon, E. Holmes, J.K. Nicholson, T.M.D. Ebbels, Intra- and Interlaboratory Reproducibility 
of Ultra Performance Liquid Chromatography-Time-of-Flight Mass Spectrometry for Urinary 
Metabolic Profiling, Anal. Chem. 84(5) (2012) 2424-2432. 
[81] H.G. Gika, G.A. Theodoridis, J.E. Wingate, I.D. Wilson, Within-day reproducibility of an HPLC-MS-
Based method for metabonomic analysis: Application to human urine, J. Proteome Res. 6(8) (2007) 
3291-3303. 
[82] H.G. Gika, G.A. Theodoridis, M. Earll, I.D. Wilson, A QC approach to the determination of day-to-
day reproducibility and robustness of LC-MS methods for global metabolite profiling in 
metabonomics/metabolomics, Bioanalysis 4(18) (2012) 2239-47. 
[83] E.J. Want, I.D. Wilson, H. Gika, G. Theodoridis, R.S. Plumb, J. Shockcor, E. Holmes, J.K. Nicholson, 
Global metabolic profiling procedures for urine using UPLC-MS, Nat. Protoc. 5(6) (2010) 1005-1018. 
[84] P. Kiefer, N. Delmotte, J.A. Vorholt, Nanoscale Ion-Pair Reversed-Phase HPLC−MS for Sensitive 
Metabolome Analysis, Anal. Chem. 83(3) (2011) 850-855. 
[85] R. Garcia-Villalba, A. Carrasco-Pancorbo, G. Zurek, M. Behrens, C. Bassmann, A. Segura-
Carretero, A. Fernandez-Gutierrez, Nano and rapid resolution liquid chromatography-electrospray 
ionization-time of flight mass spectrometry to identify and quantify phenolic compounds in olive oil, 
J. Sep. Sci. 33(14) (2010) 2069-78. 
[86] Y. Yang, C. Cruickshank, M. Armstrong, S. Mahaffey, R. Reisdorph, N. Reisdorph, New sample 
preparation approach for mass spectrometry-based profiling of plasma results in improved coverage 
of metabolome, J Chromatogr A 1300 (2013) 217-26. 
[87] S. Tulipani, R. Llorach, M. Urpi-Sarda, C. Andres-Lacueva, Comparative analysis of sample 
preparation methods to handle the complexity of the blood fluid metabolome: when less is more, 
Anal Chem 85(1) (2013) 341-8. 
[88] F. Michopoulos, L. Lai, H. Gika, G. Theodoridis, I. Wilson, UPLC-MS-based analysis of human 
plasma for metabonomics using solvent precipitation or solid phase extraction, J Proteome Res 8(4) 
(2009) 2114-21. 
[89] D. Vuckovic, Current trends and challenges in sample preparation for global metabolomics using 
liquid chromatography-mass spectrometry, Anal. Bioanal. Chem. 403(6) (2012) 1523-1548. 
[90] R.-J. Raterink, P.W. Lindenburg, R.J. Vreeken, R. Ramautar, T. Hankemeier, Recent 
developments in sample-pretreatment techniques for mass spectrometry-based metabolomics, 
TrAC, Trends Anal. Chem. 61(0) (2014) 157-167. 
[91] P. Yin, G. Xu, Current state-of-the-art of nontargeted metabolomics based on liquid 
chromatography–mass spectrometry with special emphasis in clinical applications, J. Chromatogr. A 
1374(0) (2014) 1-13. 
24 
 
[92] A. Berlioz-Barbier, A. Bulete, A. Fildier, J. Garric, E. Vulliet, Non-targeted investigation of benthic 
invertebrates (Chironomus riparius) exposed to wastewater treatment plant effluents using 
nanoliquid chromatography coupled to high-resolution mass spectrometry, Chemosphere 196 
(2018) 347-353. 
[93] Y.H. Yang, C. Cruickshank, M. Armstrong, S. Mahaffey, R. Reisdorph, N. Reisdorph, New sample 
preparation approach for mass spectrometry-based profiling of plasma results in improved coverage 
of metabolome, J. Chromatogr. A 1300 (2013) 217-226. 
[94] E. Gionfriddo, E. Boyaci, J. Pawliszyn, New Generation of Solid-Phase Microextraction Coatings 
for Complementary Separation Approaches: A Step toward Comprehensive Metabolomics and 
Multiresidue Analyses in Complex Matrices, Anal Chem 89(7) (2017) 4046-4054. 
[95] F. David, P. Sandra, Stir bar sorptive extraction for trace analysis, J Chromatogr A 1152(1-2) 
(2007) 54-69. 
[96] M. Abdel-Rehim, Recent advances in microextraction by packed sorbent for bioanalysis, J 
Chromatogr A 1217(16) (2010) 2569-80. 
[97] B. Bojko, N. Reyes-Garcés, V. Bessonneau, K. Goryński, F. Mousavi, E.A. Souza Silva, J. Pawliszyn, 
Solid-phase microextraction in metabolomics, TrAC Trends in Analytical Chemistry 61(Supplement C) 
(2014) 168-180. 
[98] X. Luo, L. Li, Metabolomics of Small Numbers of Cells: Metabolomic Profiling of 100, 1000 and 
10000 Human Breast Cancer Cells, Anal Chem  (2017). 
[99] M.J. Gouveia, P.J. Brindley, L.L. Santos, J.M.C. da Costa, P. Gomes, N. Vale, Mass spectrometry 
techniques in the survey of steroid metabolites as potential disease biomarkers: A review, 
Metabolism-Clinical and Experimental 62(9) (2013) 1206-1217. 
[100] R.K. Singh, S. Gupta, S. Dastidar, A. Ray, Cysteinyl Leukotrienes and Their Receptors: Molecular 
and Functional Characteristics, Pharmacology 85(6) (2010) 336-349. 
[101] S. Fernández-Arroyo, A. Gómez-Martínez, L. Rocamora-Reverte, R. Quirantes-Piné, A. Segura-
Carretero, A. Fernández-Gutiérrez, J.A. Ferragut, Application of nanoLC-ESI-TOF-MS for the 
metabolomic analysis of phenolic compounds from extra-virgin olive oil in treated colon-cancer cells, 
J. Pharm. Biomed. Anal. 63 (2012) 128-134. 
[102] M. Ciebiada, P. Gorski, A. Antczak, Eicosanoids in exhaled breath condensate and 
bronchoalveolar lavage fluid of patients with primary lung cancer, Dis. Markers 32(5) (2012) 329-35. 
[103] T. Uehara, A. Yokoi, K. Aoshima, S. Tanaka, T. Kadowaki, M. Tanaka, Y. Oda, Quantitative 
Phosphorus Metabolomics Using Nanoflow Liquid Chromatography-Tandem Mass Spectrometry and 
Culture-Derived Comprehensive Global Internal Standards, Anal Chem 81(10) (2009) 3836-3842. 
[104] S.M. Rappaport, D.K. Barupal, D. Wishart, P. Vineis, A. Scalbert, The blood exposome and its 
role in discovering causes of disease, Environ Health Perspect 122(8) (2014) 769-74. 
[105] C.P. Wild, The exposome: from concept to utility, International Journal of Epidemiology 41(1) 
(2012) 24-32. 
[106] R. García-Villalba, A. Carrasco-Pancorbo, C. Oliveras-Ferraros, J.A. Menéndez, A. Segura-
Carretero, A. Fernández-Gutiérrez, Uptake and metabolism of olive oil polyphenols in human breast 
cancer cells using nano-liquid chromatography coupled to electrospray ionization-time of flight-mass 
spectrometry, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life 
Sciences 898 (2012) 69-77. 
[107] Q. Liu, J.S. Cobb, J.L. Johnson, Q. Wang, J.N. Agar, Performance Comparisons of Nano-LC 
Systems, Electrospray Sources and LC-MS-MS Platforms, J. Chromatogr. Sci. 52 (2013) 120-127. 
[108] C.X. Zhao, Z.M. Wu, G. Xue, J. Wang, Y.N. Zhao, Z.X. Xu, D.Y. Lin, G. Herbert, Y.W. Chang, K.Y. 
Cai, G.W. Xu, Ultra-high capacity liquid chromatography chip/quadrupole time-of-flight mass 
spectrometry for pharmaceutical analysis, J. Chromatogr. A 1218(23) (2011) 3669-3674. 
[109] J. Hernandez-Borges, G. D'Orazio, Z. Aturki, S. Fanali, Nano-liquid chromatography analysis of 
dansylated biogenic amines in wines, J. Chromatogr. A 1147(2) (2007) 192-199. 
[110] J.Y. Lee, J.Y. Kim, G.W. Park, M.H. Cheon, K.H. Kwon, Y.H. Ahn, M.H. Moon, H.J. Lee, Y.K. Paik, 
J.S. Yoo, Targeted Mass Spectrometric Approach for Biomarker Discovery and Validation with 
25 
 
Nonglycosylated Tryptic Peptides from N-linked Glycoproteins in Human Plasma, Mol. Cell. 
Proteomics 10(12) (2011) M111-009290. 
[111] P.P. Parte, P. Rao, S. Redij, V. Lobo, S.J. D'Souza, R. Gajbhiye, V. Kulkarni, Sperm 
phosphoproteome profiling by ultra performance liquid chromatography followed by data 
independent analysis (LC-MSE) reveals altered proteomic signatures in asthenozoospermia, J. 
Proteomics 75(18) (2012) 5861-5871. 
[112] S.H. Hsieh, H.Y. Huang, S. Lee, Determination of eight penicillin antibiotics in pharmaceuticals, 
milk and porcine tissues by nano-liquid chromatography, J. Chromatogr. A 1216(43) (2009) 7186-
7194. 
[113] K. Lanckmans, A. Van Eeckhaut, S. Sarre, I. Smolders, Y. Michotte, Capillary and nano-liquid 
chromatography–tandem mass spectrometry for the quantification of small molecules in 
microdialysis samples: Comparison with microbore dimensions, J. Chromatogr. A 1131(1–2) (2006) 
166-175. 
[114] M.d.M. Contreras, D. Arráez-Román, A. Fernández-Gutiérrez, A. Segura-Carretero, Nano-liquid 
chromatography coupled to time-of-flight mass spectrometry for phenolic profiling: A case study in 
cranberry syrups, Talanta 132(0) (2015) 929-938. 
[115] T. Köcher, P. Pichler, M. De Pra, L. Rieux, R. Swart, K. Mechtler, Development and performance 
evaluation of an ultralow flow nanoliquid chromatography-tandem mass spectrometry set-up, 
Proteomics 14(17-18) (2014) 1999-2007. 
[116] M.S. Bereman, T.I. Williams, D.C. Muddiman, Development of a nanoLC LTQ Orbitrap Mass 
Spectrometric Method for Profiling Glycans Derived from Plasma from Healthy, Benign Tumor 
Control, and Epithelial Ovarian Cancer Patients, Anal. Chem. 81(3) (2008) 1130-1136. 
[117] X. Duan, R. Young, R.M. Straubinger, B. Page, J. Cao, H. Wang, H. Yu, J.M. Canty, J. Qu, A 
Straightforward and Highly Efficient Precipitation/On-Pellet Digestion Procedure Coupled with a 
Long Gradient Nano-LC Separation and Orbitrap Mass Spectrometry for Label-Free Expression 
Profiling of the Swine Heart Mitochondrial Proteome, J. Proteome Res. 8(6) (2009) 2838-2850. 
[118] S. Ito, S. Yoshioka, I. Ogata, A. Takeda, E. Yamashita, K. Deguchi, Nanoflow gradient generator 
for capillary high-performance liquid chromatography-nanoelectrospray mass spectrometry, J. 
Chromatogr. A 1051(1-2) (2004) 19-23. 
[119] M. Ninonuevo, H.J. An, H.F. Yin, K. Killeen, R. Grimm, R. Ward, B. German, C. Lebrilla, 
Nanoliquid chromatography-mass spectrometry of oligosaccharides employing graphitized carbon 
chromatography on microchip with a high-accuracy mass analyzer, Electrophoresis 26(19) (2005) 
3641-3649. 
[120] Y. Izumi, A. Okazawa, T. Bamba, A. Kobayashi, E. Fukusaki, Development of a method for 
comprehensive and quantitative analysis of plant hormones by highly sensitive nanoflow liquid 
chromatography-electrospray ionization-ion trap mass spectrometry, Anal. Chim. Acta 648(2) (2009) 
215-225. 
[121] A. Cappiello, G. Famiglini, F. Mangani, P. Palma, A. Siviero, Nano-high-performance liquid 
chromatography-electron ionization mass spectrometry approach for environmental analysis, Anal. 
Chim. Acta 493(2) (2003) 125-136. 
[122] J. Masuda, D.A. Maynard, M. Nishimura, T. Uedac, J.A. Kowalak, S.P. Markey, Fully automated 
micro- and nanoscale one- or two-dimensional high-performance liquid chromatography system for 
liquid chromatography-mass spectrometry compatible with non-volatile salts for ion exchange 
chromatography, J. Chromatogr. A 1063(1-2) (2005) 57-69. 
[123] S.R. Wilson, H. Malerod, A. Holm, P. Molander, E. Lundanes, T. Greibrokk, On-line SPE-nano-LC-
nanospray-MS for rapid and sensitive determination of perfluorooctanoic acid and perfluorooctane 
sulfonate in river water, J. Chromatogr. Sci. 45(3) (2007) 146-152. 
[124] K. Buonasera, G. D'Orazio, S. Fanali, P. Dugo, L. Mondello, Separation of organophosphorus 
pesticides by using nano-liquid chromatography, J. Chromatogr. A 1216(18) (2009) 3970-3976. 
26 
 
[125] A. Rocco, C. Fanali, L. Dugo, L. Mondello, A nano-LC/UV method for the analysis of principal 
phenolic compounds in commercial citrus juices and evaluation of antioxidant potential, 
Electrophoresis 35(11) (2014) 1701-1708. 
[126] C. Fanali, L. Dugo, A. Rocco, Nano-liquid chromatography in nutraceutical analysis: 
Determination of polyphenols in bee pollen, J. Chromatogr. A 1313 (2013) 270-274. 
[127] C. Fanali, L. Dugo, G. D'Orazio, M. Lirangi, M. Dacha, P. Dugo, L. Mondello, Analysis of 
anthocyanins in commercial fruit juices by using nano-liquid chromatography-electrospray-mass 
spectrometry and high-performance liquid chromatography with UV-vis detector, J. Sep. Sci. 34(2) 
(2011) 150-159. 
[128] S. Fanali, Z. Aturki, G. D'Orazio, A. Rocco, A. Ferranti, L. Mercolini, M.A. Raggi, Analysis of Aloe-
based phytotherapeutic products by using nano-LC-MS, J. Sep. Sci. 33(17-18) (2010) 2663-2670. 
[129] G. Merola, Z. Aturki, G. D'Orazio, R. Gottardo, T. Macchia, F. Tagliaro, S. Fanali, Analysis of 
synthetic cannabinoids in herbal blends by means of nano-liquid chromatography, J. Pharm. Biomed. 
Anal. 71 (2012) 45-53. 
[130] L. Hu, K.-S. Boos, M. Ye, R.a. Wu, H. Zou, Selective on-line serum peptide extraction and 
multidimensional separation by coupling a restricted-access material-based capillary trap column 
with nanoliquid chromatography–tandem mass spectrometry, J. Chromatogr. A 1216(28) (2009) 
5377-5384. 
[131] Y. Shen, N. Tolic, C. Masselon, L. Pasa-Tolic, D.G. Camp, K.K. Hixson, R. Zhao, G.A. Anderson, 
R.D. Smith, Ultrasensitive proteomics using high-efficiency on-line micro-SPE-NanoLC-NanoESI MS 
and MS/MS, Anal. Chem. 76(1) (2004) 144-154. 
[132] D. Thomas, M. Eberle, S. Schiffmann, D.D. Zhang, G. Geisslinger, N. Ferreirós, Nano-LC-MS/MS 
for the quantitation of ceramides in mice cerebrospinal fluid using minimal sample volume, Talanta 
116 (2013) 912-918. 
[133] M.C. Parkin, A.M. Longmoore, S.C. Turfus, R.A. Braithwaite, D.A. Cowan, S. Elliott, A.T. Kicman, 
Detection of ketamine and its metabolites in human hair using an integrated nanoflow liquid 
chromatography column and electrospray emitter fritted with a single porous 10μm bead, J. 
Chromatogr. A 1277 (2013) 1-6. 
[134] R. Quirantes-Pine, V. Verardo, D. Arraez-Roman, S. Fernandez-Arroyo, V. Micol, M.F. Caboni, A. 
Segura-Carretero, A. Fernandez-Gutierrez, Evaluation of different extraction approaches for the 
determination of phenolic compounds and their metabolites in plasma by nanoLC-ESI-TOF-MS, Anal. 
Bioanal. Chem. 404(10) (2012) 3081-3090. 
[135] M.L. Chen, X.M. Fu, J.Q. Liu, T.T. Ye, S.Y. Hou, Y.Q. Huang, B.F. Yuan, Y. Wu, Y.Q. Feng, Highly 
sensitive and quantitative profiling of acidic phytohormones using derivatization approach coupled 
with nano-LC-ESI-Q-TOF-MS analysis, J. Chromatogr. B 905 (2012) 67-74. 
[136] L.R. Ruhaak, S.L. Taylor, S. Miyamoto, K. Kelly, G.S. Leiserowitz, D. Gandara, C.B. Lebrilla, K. 
Kim, Chip-based nLC-TOF-MS is a highly stable technology for large-scale high-throughput analyses, 
Anal. Bioanal. Chem. 405(14) (2013) 4953-4958. 
[137] L. Wilson, A. Arabshahi, B. Simons, J.K. Prasain, S. Barnes, Improved high sensitivity analysis of 
polyphenols and their metabolites by nano-liquid chromatography–mass spectrometry, Arch. 
Biochem. Biophys. 1(0) (2014) 3-11. 
[138] T. Iven, C. Herrfurth, E. Hornung, M. Heilmann, P. Hofvander, S. Stymne, L.H. Zhu, I. Feussner, 
Wax ester profiling of seed oil by nano-electrospray ionization tandem mass spectrometry, Plant 
Methods 9 (2013). 
[139] A. Berlioz-Barbier, A. Buleté, J. Faburé, J. Garric, C. Cren-Olivé, E. Vulliet, Multi-residue analysis 
of emerging pollutants in benthic invertebrates by modified micro-quick-easy-cheap-efficient-
rugged-safe extraction and nanoliquid chromatography–nanospray–tandem mass spectrometry 
analysis, J. Chromatogr. A 1367(0) (2014) 16-32. 
[140] A. Berlioz-Barbier, R. Baudot, L. Wiest, M. Gust, J. Garric, C. Cren-Olivé, A. Buleté, 
MicroQuEChERS–nanoliquid chromatography–nanospray–tandem mass spectrometry for the 
27 
 
detection and quantification of trace pharmaceuticals in benthic invertebrates, Talanta 132(0) (2015) 
796-802. 
[141] M. Sordet, A. Berlioz-Barbier, A. Bulete, J. Garric, E. Vulliet, Quantification of emerging 
micropollutants in an amphipod crustacean by nanoliquid chromatography coupled to mass 
spectrometry using multiple reaction monitoring cubed mode, J Chromatogr A 1456 (2016) 217-25. 
28 
 
Table 1: Overview of existing nLC-nESI instrumentations and associated parameters (nanocolumns 
characteristics, flow rate, injection volume, run time and matrices) used in metabolomic studies. 
nLC MS Flow 
rate  
(nL/min
) 
Colum
n ID 
(µm) 
Lengt
h  
(mm) 
Particl
e  
size 
(µm) 
Phase Injectio
n  
volume 
(nL) 
Run 
time  
(min
) 
Matrice Refs 
      
Thermo 
Ultimate 
3000 nano 
Thermo 
LTQ-
Orbitrap 
1000 150 150 5 HILIC 
Not 
defined 
60 CSF [69] 
Eksigent 
nanoLC 
Ultra 
Thermo 
LTQ-
Orbitrap 
500 100 100 5 C18 1000 45 
In vitro cell 
lines  
[84] 
Bruker 
EASY-nLC 
Bruker 
MicroTO
F 
300 75 100 3 C18 5000 47 
In vitro cell 
lines 
[106
] 
Agilent 
1100 Series 
Bruker 
MicroTO
F 
312 75 150 3 C18 6.25 23 Urine [65] 
Waters 
nanoAcquit
y 
Orbitrap 
Elite 
300 75 100 1.7 
BEH 
C18 
2000 60 
In vitro cell 
lines 
[70] 
Waters 
nanoAcquit
y 
Waters 
XEVO G2 
QTOF 
700 100 100 1.8 HSS-T3 500 50 
Urine/Plasm
a 
[73] 
Waters 
nanoAcquit
y 
Waters 
XEVO G2 
QTOF 
700 100 100 1.7 
BEH 
C18 
500 50 Plasma [11] 
Waters 
nanoAcquit
y 
Waters 
XEVO G2 
QTOF 
700 100 100 1.8 HSS-T3 500 50 Urine [62] 
Waters 
nanoAcquit
y 
Waters 
QTOF 
Premier 
350 75 200 1.7 
Acclaim 
Pepma
x C18 
5000 45 
Urine and 
sweat 
[68] 
Waters 
nanoAcquit
y 
Waters 
XEVO G2 
QTOF 
700 100 100 1.8 HSS-T3 500 50 Urine [63] 
Eksigent 
415 - 
nanoflex 
cHiPLC 
Sciex 
5600 
Triple 
TOF 
300 200 150 
Not 
define
d 
C18 5000 24 Faeces [66] 
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Waters 
nanoAcquit
y 
Waters 
XEVO G2 
QTOF 
700 100 100 1.8 HSS-T3 500 50 Urine [64] 
Waters 
nanoAcquit
y 
Waters 
XEVO G2 
QTOF 
700 100 100 1.8 HSS-T3 500 50 
Plasma and 
tissues 
[23] 
Agilent 
1100 Series 
Thermo 
7-T LTQ-
FT Ultra  
300 75 120 3 C18 2000 105 
Exhaled 
breath 
condensate 
[67] 
Waters 
nanoAcquit
y 
Bruker 
Impact 
HD QTOF 
350 75 150 2 
Acclaim 
Pepma
x C18 
11.4 
pmol  
of 
sample 
45 
In vitro cell 
lines  
[98] 
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Table 2: Relative standard deviation (RSD) of retention time (RT) for small molecules (<1000 Da) 
analysed in different matrices using direct (D) and split (S) flow nLC platforms. 
Analyte Matrix Flow 
rate 
(nL/
min) 
RT 
(%RS
D) 
nLC system Flow 
type 
Ref 
6 Deuterated 
standards 
Plasma and 
urine 
700 <0.20
% 
Waters nanoAcquity UPLC D [7
3] 
100 
(Xeno)metabolites 
Plasma 700 <1.9% Waters nanoAcquity UPLC D [1
1] 
100 Metabolites Urine 700 <1.9% Waters nanoAcquity UPLC D [6
2] 
8 Amino acids Urine and 
sweat 
350 <1.1% Waters nanoAcquity UPLC D [6
8] 
Tryptic digests Bovine serum 
albumin 
325 0.73% Proxeon EASY-nLC D [1
07
] 
Tryptic digests Bovine serum 
albumin 
325 0.66% Waters nanoAcquity UPLC D [1
07
] 
Tryptic digests Bovine serum 
albumin 
325 0.87% Eksigent nanoLC-Ultra D [1
07
] 
Tryptic digests Bovine serum 
albumin 
325 2.2% Eksigent nanoLC-2D, D [1
07
] 
Pharmaceuticals Standard 
solution 
300 <0.50
% 
Agilent 1200 HPLC D [1
08
] 
Biogenic amines Wine 634 <1.2% Dionex Ultimate Capillary HPLC D [1
09
] 
Nonglycosylated 
tryptic peptides 
Plasma 450-
500 
<1.6% Waters nanoAcquity UPLC D [1
10
] 
Phosphoproteins Semen 300 2.0% Waters nanoAcquity UPLC D [1
11
] 
Penicillin antibiotics Standard 
solution 
200 <0.35
% 
Dionex Ultimate 3000 nano LC D [1
12
] 
Pharmaceuticals Standard 
solution 
300 <0.50
% 
Dionex Ultimate D [1
13
] 
Phenolic 
compounds 
Standard 
solution 
300 ≤0.80
% 
Bruker Easy-nLC
TM 
D [1
14
] 
Peptides HeLa protein 
standard 
20-
50 
≤0.30
% 
Thermo Ultimate 3000 RSLC nano 
LC 
D [1
15
] 
Glycans Plasma 500 <0.50 Eksigent Technologies nanoLC 2D D [1
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% 16
] 
Peptides Mitochondrial 
extracts 
200 ≤0.65
% 
Eksigent direct-flow nano-LC 
pumps 
D [1
17
] 
Parabens Standard 
solution 
200 <0.50
% 
AT10PV nanoGR generator D [1
18
] 
Pharmaceuticals Standard 
solution 
800 <2.0% Rheos 2000 micro-pump S [3
8] 
Oligosaccharides Standard 
solution 
300 <0.50
% 
Agilent 1000 HPLC S [1
19
] 
Plant hormones Tobacco seeds 350 ≤1.1% LC Packings Ultimate S [1
20
] 
Hormones, 
pesticides and PAHs 
Standard 
solution 
250 <2.0% Kontron instruments 420 dual-
pump binary gradient HPLC 
S [1
21
] 
Tryptic digests Bovine serum 
albumin 
400 <2.5% LC-10ADVP solvent delivery pump S [1
22
] 
Perfluorooctanoic 
acid/ sulfonate 
River water 700 <1.0% Agilent 1100 HPLC S [1
23
] 
Organophosphorous 
pesticides 
Standard 
solution 
360 <1.0% Dionex Ultimate Capillary HPLC S [1
24
] 
Flavanones Citrus juice 500 <2.4% Spectra System P2000 HPLC pump S [1
25
] 
Polyphenols Bee pollen 500 <1.8% Spectra System P2000 HPLC pump S [1
26
] 
Anthocyanins Fruit juices 400 <3.4% Dionex Ultimate–LC Packings  S [1
27
] 
Aloe-based 
phytotherapeutics  
Standard 
solution and 
leaf 
350 <1.5% Rheos 2000 micro-pump S [1
28
] 
Synthetic 
cannabinoids 
Herbal mixtures 500 <1.7% Rheos 2000 micro-LC pump S [1
29
] 
Peptides Serum 200 <0.80
% 
Finnigan quaternary Surveyor 
pump 
S [1
30
] 
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Table 3: Relative standard deviation (RSD) of peak area for small molecules (<1000 Da) analysed in 
different matrices using nLC-nESI platforms 
Analyte Matrix Peak area 
(%RSD) 
Emitter 
material 
Emitter 
ID 
Ref 
Deuterated and normal standards Standard solution/ urine 
and plasma 
<18% Fused silica 10 µm [73
] 
Cationic metabolites Cerebrospinal fluid <20% Fused silica 8 µm [69
] 
8 Amino acids Urine and sweat <7% Fused silica 5 µm Z. 
L[6
8] 
Tryptic digests Cellular protein extract <15% Fused silica 5 µm [13
1] 
Ceramides Cerebral spinal fluid <15% Fused silica 10 µm [13
2] 
Pharmaceuticals Standard solution <11% Fused silica 10 µm [11
3] 
Anthocyanins Fruit juice <16% Fused silica 25 µm [12
7] 
Pharmaceuticals Standard solution 10% Fused silica 25 µm [38
] 
Perfluorooctanoic 
acid/perfluorooctane sulfonate 
River water <20% Fused silica 30 µm [12
3] 
Aloe-based phytotherapeutic 
products 
Standard solution and 
leaves 
<12.5% Fused silica 25 µm [12
8] 
Ketamine and metabolites Human hair ≤4% Tapered 
fused silica 
20 µm [13
3] 
Plant hormones Tobacco seeds <11% Tapered 
fused silica 
8-9 µm [12
0] 
Phenolics Olive oil and cell culture <4% Tapered 
fused silica 
Not 
defined 
[10
6] 
Phenolic compounds Standard solution <7% Tapered 
fused silica 
Not 
defined 
[13
4] 
Phenolic compounds Standard solution <15% Tapered 
fused silica 
Not 
defined 
[11
4] 
Metabolite standards Cell extracts <23% Silica 10 µm [84
] 
Pharmaceuticals Standard solution and 
plasma 
<10% Not defined 75 µm [10
8] 
Phytohormones Leaves <12% Not defined 8 µm [13
5] 
Peptides Serum  ≤25% Not defined 5 µm [13
0] 
50 Glycans Serum standard <10% Not defined Not 
defined 
[13
6] 
Polyphenols Urine ≤13% Not defined Not 
defined 
[13
7] 
Penicillin antibiotics Milk, liver, kidney <8% Not defined Not 
defined 
[11
2] 
Wax esters Seed oil extracts <5% Not defined Not 
defined 
[13
8] 
Oligosaccharides Standard solution <5% Not defined Not 
defined 
[11
9] 
Environmental contaminants Benthic tissue extracts <13% Not defined Not 
defined 
[13
9] 
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Pharmaceuticals Benthic tissue extracts <15% Not defined Not 
defined 
[14
0] 
Carbamazepine, testosterone and 
oxazepam 
Gammarus fossarum <12% Not defined Not 
defined 
[14
1] 
Peptides Mitochondrial extracts <12% Not defined Not 
defined 
[11
7] 
 
 
Table 4: Advantages and drawbacks of nLC-nESI compared to conventional LC-ESI platforms for 
metabolomic analysis 
Advantages  Drawbacks  
Increased ionisation efficiency in the source and 
transfer efficiency in the mass spectrometer  
More care to be done for sample preparation  
Reduced chromatographic dilution Less sample throughput due to longer LC run time 
More comprehensive analysis due to the detection of 
trace level metabolites  
More prone to column/emitter blockages 
Reduced cost and environmental impact by using less 
solvent 
Less array of column chemistries readily available 
Reduce need for desolvation gas and temperature in 
the source 
More expertise needed 
Possibility to convert existing proteomic platforms for 
metabolomic analysis 
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Figure captions 
Figure 1: Base peak intensity (BPI) chromatograms of a standard mixture of compounds analysed by 
BEH C18 300 and 130 Å and HSS T3 100 Å nUHPLC columns. The base peak intensity peaks of 
selected standards are labelled to demonstrate the different retention characteristics of each 
column. TIC = total ion count. 1, unretained polar compounds, 2, metropolol; 3, venlafaxine; 4, 
propranolol; 5, carbamazepine; 6, testosterone; 7, androstenedione; 8, sphingosine; 9, diazinon; 10, 
tris(2-butoxyethyl) phosphate. Reproduced with permission from Ref [73]. 
 
Figure 2: Positive ESI mode base peak intensity (BPI) of pooled HIV patient urine run using nLC-nESI-
TOFMS (A) and extracted ion chromatograms of protease inhibitors and their metabolites (B) as 
described in [64]. D= darunavir, DM1-3 = darunavir metabolites 1-3, A= atazanavir, AM1-5 = 
atazanavir metabolites 1-5, R=ritonavir, RM1-2 = ritonavir metabolites 1-2). Samples run on a Waters 
nanoAcquity-nanoESI-XEVO G2 TOFMS with a 100 mm x 100 µm x 2.8 µm x 100 Å HSS T3 column. 
 
Figure 3. Example of base peak intensity (BPI) chromatograms (A) of testis extracts from fish 
exposed to wastewater effluent in positive (+ESI) and negative (-ESI) modes. Chromatograms B show 
overlaid signals of selected xenobiotics extracted using their exact masses. Chemical identity was 
confirmed from accurate mass, isotopic fit and fragmentation data obtained from high energy 
collisional induced dissociation and from comparison with standard compounds. Testis samples were 
extracted by Strata-X-C solid-phase extraction after phospholipid removal and profiled in –ESI or +ESI 
modes by nUHPLC-nESI-TOFMS as described in [23].1=10 
Hydroxyamitriptyline;2=Norclozapine;3=citalopram;4=Amitriptyline;5=norsertraline;6=sertraline;7=c
lopidogrel 
 
 
 
 
 
 
 
Figure 1. 
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Graphical abstract 
 
 
 
 
Highlights 
 nanoLC-nanoESI-MS offers increased ionisation efficiency for small molecule analyses 
 nanoLC-nanoESI-MS is reproducible making it suitable for metabolomics 
 Sample preparation is a key step for nanoLC-nanoESI-MS 
 Applications of nanoLC-nanoESI-MS in untargeted studies offer promising perspectives 
 
